Table 1.

mRNA expression of CTAs in tumor and TFL of HCC-patients. ¹ Percentage of hepatocellular carcinomas (HCC) expressing mRNA of the CTA–meaning a Ct-value <35 and relative expression >0.001 (n = 100); ² Mean relative expression (relative to the geometric mean of the 3 household genes- GUSB, HPRT1, PMM1) level in HCCs expressing the CTA and range; ³ Mean relative expression of the CTA in HCC expressing the CTA, relative to the relative mean expression in 3 testis tissues; ⁴ Percentage of paired tumor-free liver (TFL) tissues expressing mRNA of the CTA (n = 100); ⁵ Mean relative expression level in TFLs expressing the CTA and range; ⁶ Mean relative expression of the CTA in TFL expressing the CTA, relative to the relative mean expression in 3 testis tissues; ⁷ Percentage of non-cancerous/non-dysplastic cirrhotic liver tissues expressing the CTA (n = 35); * % in male.

CTA	mRNA-Positive HCC (%) 1	Mean in mRNA-+ HCC (Range) 2	Relative Expression HCC (Compared to Testis) 3	mRNA-Positive TFL (%) 4	Mean in mRNA-+ TFL (Range) 5	Relative Expression TFL(Compared to Testis) 6	mRNA-Positive Cirrhotic Tissue 7
CAGE1	14.4	0.082 (0.003–0.711)	0.188	2.0	0.009 (0.003–0.015)	0.020	0
CT47A1	26.8	1.311 (0.001–20.565)	0.632	6.1	0.255 (0.01–0.769)	0.123	0
MAGEA1	58.6	0.403 (0.003–1.926)	4.170	13.0	0.055 (0.005–0.188)	0.567	0
MAGEA9	14.1	0.41 (0.001–4.953)	2.848	1.0	0.035 (0.035–0.035)	0.243	0
MAGEA10	12.4	0.123 (0.002–0.518)	1.080	4.1	0.028 (0.004–0.088)	0.249	0
MAGEB2	24.2	0.395 (0.002–2.4)	0.761	6.0	0.053 (0.018–0.127)	0.102	0
MAGEC1	47.5	0.109 (0.001–0.841)	0.407	32.0	0.047 (0.002–0.466)	0.174	28.6
MAGEC2	55.6	0.692 (0.001–9.305)	1.542	19.0	0.041 (0.003–0.28)	0.091	25.7
NYESO1	10.1	0.13 (0.007–1.04)	0.525	1.0	0.018 (0.018–0.018)	0.071	0
PAGE1	18.2	0.37 (0.002–2.225)	1.001	5.0	0.059 (0.009–0.179)	0.159	2.9
SLCO6A1	25.8	0.095 (0.002–0.411)	0.053	4.1	0.011 (0.004–0.017)	0.006	2.9
TSPY *	21.0	0.827 (0.004–7.401)	34.135	4.8	0.218 (0.001–0.641)	9.012	4.2